Cohort study of serological biomarkers for interstitial lung disease in patients with rheumatoid arthritis

ObjectiveInterstitial lung disease (ILD) is an important cause of mortality in patients with rheumatoid arthritis (RA). Early RA-ILD detection is essential to improve prognosis. Here, we investigated eight serological biomarkers that may contribute to RA-ILD detection. MethodFifty-five patients from the Early Rheumatoid Arthritis Program were evaluated for ILD with high-resolution computed tomography (HRCT) and pulmonary function tests (PFTs) using the SCAPIS protocol. Blood samples were obtained for biomarker analysis, and patients' clinical records were reviewed. We defined ILD using five different models based on the measurements used to confirm ILD: Model A = HRCT; B = PFTs; C = A plus B; D = C plus symptoms; and E = D plus inhalations. ResultsAmong 55 patients, two had an ILD diagnosis before the study, but over one-third fulfilled the ILD criteria. Cancer antigen 15-3 (CA15-3) and matrix metalloproteinase-7 (MMP-7) differentiated between RA with and without ILD (all p < 0.05). Surfactant protein D (SP-D) showed similar trends, as did macrophage inflammatory protein-1 beta (MIP-1 beta) and chitinase 3-like protein-1 (YKL-40). Based on Pearson's correlation coefficients, MIP-1 beta and YKL-40 were significantly correlated with DAS28 (MIP-1 beta: 0.3; YKL-40: 0.4), ESR (MIP-1 beta: 0.3; YKL-40: 0.4), and CRP (only MIP-1 beta: 0.4) (all p < 0.05). CA15-3 was correlated with rheumatoid factor and anti-citrullinated peptide antibodies (Pearson's correlation 0.3; both p = 0.03). ConclusionsCA15-3 was the most significant biomarker for ILD detection in RA patients with stable low disease activity, closely followed by MMP-7. SP-D, MIP-1 beta, and YKL-40 may also contribute to RA-ILD diagnosis.